Otsuka's top selling drug Rxulti is expected to get FDA approval for a new indication in early 2025. The company has reduced profit guidance for 1H24. Otsuka targets for revenue of ¥2.5T by 2028.
What is covered in the Full Insight:
Introduction
Indication Expansion of Rexulti
Strong 1Q24 Performance
1H24 Guidance Revision
New Medium-Term Management Plan
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.